GB201716408D0 - Stem cell microparticles for cancer therapy - Google Patents

Stem cell microparticles for cancer therapy

Info

Publication number
GB201716408D0
GB201716408D0 GBGB1716408.8A GB201716408A GB201716408D0 GB 201716408 D0 GB201716408 D0 GB 201716408D0 GB 201716408 A GB201716408 A GB 201716408A GB 201716408 D0 GB201716408 D0 GB 201716408D0
Authority
GB
United Kingdom
Prior art keywords
stem cell
cancer therapy
cell microparticles
microparticles
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1716408.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reneuron Ltd
Original Assignee
Reneuron Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reneuron Ltd filed Critical Reneuron Ltd
Priority to GBGB1716408.8A priority Critical patent/GB201716408D0/en
Publication of GB201716408D0 publication Critical patent/GB201716408D0/en
Priority to PCT/GB2018/052852 priority patent/WO2019069093A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C12N2502/088—Coculture with; Conditioned medium produced by cells of the nervous system neural stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1716408.8A 2017-10-06 2017-10-06 Stem cell microparticles for cancer therapy Ceased GB201716408D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1716408.8A GB201716408D0 (en) 2017-10-06 2017-10-06 Stem cell microparticles for cancer therapy
PCT/GB2018/052852 WO2019069093A1 (en) 2017-10-06 2018-10-05 Stem cell microparticles for cancer therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1716408.8A GB201716408D0 (en) 2017-10-06 2017-10-06 Stem cell microparticles for cancer therapy

Publications (1)

Publication Number Publication Date
GB201716408D0 true GB201716408D0 (en) 2017-11-22

Family

ID=60326655

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1716408.8A Ceased GB201716408D0 (en) 2017-10-06 2017-10-06 Stem cell microparticles for cancer therapy

Country Status (2)

Country Link
GB (1) GB201716408D0 (en)
WO (1) WO2019069093A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110075122B (en) * 2019-05-09 2021-04-20 复旦大学附属中山医院 Liver cancer therapeutic exosome medicine
KR102184428B1 (en) * 2020-05-25 2020-11-30 주식회사 씨케이엑소젠 Method for preparing exosomes from mesenchymal stem cells and culture solution and culture solution produced from the same
CN111920700B (en) * 2020-09-17 2021-01-29 北京达熙生物科技有限公司 Preparation technology of stem cell exosome and application of stem cell exosome in medicines and cosmetics
CN113583965A (en) * 2021-08-05 2021-11-02 大连干细胞与精准医学创新研究院 Condition immortalized human neural stem cell-derived cell membrane nano vesicle preparation as well as preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2877187B1 (en) * 2012-07-19 2019-06-12 Reneuron Limited Stem cell microparticles
ES2927175T3 (en) * 2013-02-12 2022-11-03 Reneuron Ltd Microparticle production method
GB201317887D0 (en) * 2013-10-09 2013-11-20 Reneuron Ltd Product
WO2015022545A2 (en) * 2013-08-14 2015-02-19 Reneuron Limited Stem cell microparticles and mirna

Also Published As

Publication number Publication date
WO2019069093A1 (en) 2019-04-11

Similar Documents

Publication Publication Date Title
IL261468A (en) Uterine cancer treatments
IL254705A0 (en) Combination therapy for cancer
ZA201702382B (en) Combination therapy for cancer
HK1258319A1 (en) Cancer therapy
HK1231381A1 (en) Combination therapy for cancer
IL246607A0 (en) Improved cell compositions and methods for cancer therapy
PT3609497T (en) Combination therapy for prostate cancer
IL246761A0 (en) Combination therapy for cancer
GB201613078D0 (en) Stem cells and cancer
GB201716408D0 (en) Stem cell microparticles for cancer therapy
GB201519734D0 (en) Cancer therapy
GB201704909D0 (en) Cancer therapy
HK1254687A1 (en) Combination therapy for cancer
GB201711855D0 (en) Cancer therapy
HRP20210383T8 (en) Combination therapy for cancer
GB201711250D0 (en) Cancer therapy
GB201710198D0 (en) Cancer therapy
GB201706046D0 (en) Cancer therapy
GB201700772D0 (en) Cancer therapy
GB201706101D0 (en) Therapeutic cells
GB201601248D0 (en) Cancer therapy
GB201511609D0 (en) Cancer therapy
GB201511121D0 (en) Cancer therapy
GB201511120D0 (en) Cancer therapy
GB201417819D0 (en) Agents for cancer therapy

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)